COMPUTEX-TAIPEI
28.5.2021 10:51:07 CEST | Business Wire | Press release
COMPUTEX 2021 Virtual organized by TAITRA will take place from May 31 to June 30 online. To keep the industry updated with the most groundbreaking technology trends and provide participants with a comprehensive vision of the world, COMPUTEX extended its keynote and forum speeches to top CEOs and senior executives from leading international companies such as AMD, Arm, Intel, Micron, NVIDIA, NXP Semiconductors, Qualcomm and Supermicro.
James Huang, TAITRA Chairman, pointed out that "COMPUTEX CEO Keynote has received great interest since its introduction in 2019. This year, COMPUTEX takes it a step further by leveraging the cross-industry capabilities of technology giants, providing a platform to share insights and exchange ideas in reshaping a post-pandemic future.”
Leading CEOs and Senior Executives of Tech Giants to Deliver Keynotes
Monday, May 31, at 10:00 AM (GMT+8)
Michelle Johnston Holthaus, Executive Vice President at Intel Corporation, will speak on the Innovation Unleashed
and welcome Intel’s Steve Long, corporate vice president of Client Computing Group Sales, and Lisa Spelman, corporate vice president and general manager of the Xeon and Memory Group, to outline how Intel innovations help expand human potential by expanding technology’s potential.
Monday, May 31, at 2:00 PM (GMT+8)
Arm CEO Simon Segars will give a keynote on Sparking the World’s Post-Pandemic Recovery
, analyzing how AI will accelerate tackling complex challenges surrounding climate change, security, and equitable access to technologies and connectivity, acting thus as a remarkable force for good.
Tuesday, June 1, at 10:00 AM (GMT+8)
Dr. Lisa Su, President and CEO of AMD, will present a keynote with the theme “AMD Accelerating – The High-Performance Computing Ecosystem”
, sharing the AMD vision for the future of computing and how AMD speeds up innovation with ecosystem partners to deliver a leadership product portfolio for innovative solutions.
Tuesday, June 1, at 10:00 AM (GMT+8)
Jeff Fisher, Senior Vice President of NVIDIA’s GeForce Business Unit and Manuvir Das, Head of Enterprise Computing at NVIDIA will discuss The Transformational Power of Accelerated Computing
, from Gaming to the Enterprise Data Center. They will present the massive opportunities that GeForce PC gaming represents for the Taiwan ecosystem and shifts driving the democratization of AI and how enterprises embrace them can thrive in the coming years.
Wednesday, June 2, at 9:00 AM (GMT+8)
Sanjay Mehrotra, President and Chief Executive Officer of Micron will focus his keynote on Innovation for the Data Economy: Why Today’s Infrastructure Innovation Brings Data to Life, Powering Insights for All
, opening for the AIoT Evolution session of the COMPUTEX Forum, and sharing Micron’s vision for how data transform modern life and creates new opportunities for memory and storage innovation.
Wednesday, June 2, 10:30 AM (GMT+8)
Supermicro President, CEO & Chairman of the Board, Charles Liang, will give a keynote on Performance Begins at the Edge for 5G and Intelligent IoT
, presenting Supermicro’s newest solutions as well as its future strategy.
Wednesday, June 2, 2:00 PM (GMT+8)
NXP Semiconductors President and CEO Kurt Sievers will deliver a keynote on How AI Can Empower Industries, IoT and Automotive Industry
, the opening session for the AI Empowerment of the COMPUTEX Forum by sharing NXP Semiconductors' development and plans in AI, broadening people’s imagination of intelligent places.
Thursday, June 3, 8:40 AM (GMT+8)
Qualcomm Senior Vice President and General Manager Alex Katouzian will speak on "5G and the Future of the PC
," where he will share his unique perspectives on how 5G and the Always on, Always Connected PC are shaping the future of computing to meet the needs of a more mobile society.
For more COMPUTEX CEO Keynote and show information, please check out the official COMPUTEX website:
https://virtual.computextaipei.com.tw/events/
For more updates:
COMPUTEX website: https://www.computextaipei.com.tw
InnoVEX website: https://www.innovex.com.tw/
About COMPUTEX TAIPEI (also called COMPUTEX):
Established in 1981, COMPUTEX is one of the leading global ICT, IoT, and startup tradeshows with a complete supply chain and IoT ecosystems. Co-organized by the Taiwan External Trade Development Council (TAITRA) and Taipei Computer Association (TCA), COMPUTEX, based upon Taiwan’s complete ICT clusters, covers the whole spectrum of the ICT industry, from established brands to startups and from ICT supply chain to IoT ecosystems. With strong R&D and manufacturing capabilities and IPR protection, Taiwan is a strategic destination for foreign companies and investors looking for partners in global technology ecosystems. Follow COMPUTEX on its website at www.computextaipei.com.tw and Twitter @computex_taipei using the hashtag #COMPUTEX.
About COMPUTEX 2021 Virtual:
As a pioneer in technology, COMPUTEX has been at the forefront in embracing digital transformation. In 2021, the show will go online. Together with the key global technology players, the organizer of COMPUTEX, Taiwan External Trade Development Council (TAITRA) introduces #COMPUTEXVirtual (including its global startups and innovations showcase #InnoVEXVirtual), an AI-driven virtual platform, and aims to deliver an exceptional virtual exhibition experience beyond the distance.
About TAITRA:
Founded in 1970, TAITRA is Taiwan's foremost nonprofit trade promoting organization. Sponsored by the government and industry organizations, TAITRA assists enterprises to expand their global reach. Headquartered in Taipei, TAITRA has a team of 1,300 specialists and operates 5 local offices in Taoyuan, Hsinchu, Taichung, Tainan and Kaohsiung, as well as 63 branches worldwide. Together with Taipei World Trade Center (TWTC) and Taiwan Trade Center (TTC), TAITRA has formed a global network dedicated to promoting world trade.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210528005147/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
